Compare Astrana Health's latest earnings surge with a hand-picked 32 high quality undervalued stocks, which may also be translating solid business models into stronger profit lines.
Astrana Health attracts shareholders who buy into the idea that a scaled value based care platform with a high mix of full risk contracts can convert better medical cost management into consistent profits. The jump in third quarter and nine month net income supports that belief operationally, but it does not remove the structural exposure to Medicare Advantage and Medicaid reimbursement decisions in the near term.
The key short term catalyst remains how effectively Astrana Health manages medical cost trend and the integration of acquired members while relying heavily on government funded programs. The main immediate risk is that policy or funding changes, or a setback in delivering targeted Prospect synergies, could offset the recent earnings strength and pressure margin progress.
The most relevant fresh data point is the nine month 2026 profit line. Astrana Health reported net income of US$47.13 million for the period, with diluted EPS of US$0.95 from continuing operations. This compares with US$16.49 million and US$0.33 a year earlier, so the business is entering current catalysts with a meaningfully higher earnings base.
This higher level of profitability matters because the analyst consensus narrative on Simply Wall St focuses heavily on free cash flow generation, debt reduction and the ability to absorb integration risk from deals like Prospect. Stronger earnings give management more room to keep investing in the AI enabled operating system and full risk transitions, while still addressing balance sheet and cybersecurity related costs that sit on the risk list.
Astrana Health's narrative projects US$5.0b revenue and US$146.2 million earnings by 2029. This projection assumes 9.0% yearly revenue growth and an earnings increase of about US$105.7 million from current earnings of US$40.5 million.
Uncover why Astrana Health's fair value indicates a 62% potential upside to its current price that could narrow quickly.
One bearish twist on Astrana Health focuses on return on invested capital. The lowest analysts were pencilling in earnings of about US$114.1 million on US$5.0b revenue by 2029 before this latest earnings jump. That view is more cautious and assumes expansion investments risk weaker payoffs. You can compare these forecasts with your own expectations and see where your outlook sits.
Explore 3 other Astrana Health fair value estimates, including one that suggests it could be worth just $51.67!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider taking an independent view.
If Astrana Health's story has you thinking about where else disciplined execution and solid fundamentals might show up, the Simply Wall St Screener can help you cast a wider net without losing focus on quality.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com